FindTrial
Sign In

The value of plasma D-dimer test in hematogenous metastasis and prognosis in cancer patients

The value of plasma D-dimer test in hematogenous metastasis and prognosis in cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028178
Enrollment
Unknown
Registered
2019-12-14
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumor

Interventions

Gold Standard:1. Pathological diagnosis (puncture or operation)
imaging evaluation
detection of tumor cells in peripheral blood circulation
2. Clinical outcomes.
Index test:D-dimer, FDP

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with malignant solid tumor firstly diagnosed by pathological examination via endoscopic biopsy; Not receive anticoagulation therapy and anticancer treatment.

Exclusion criteria

Exclusion criteria: With other malignancy, trauma, hepatic insufficiency and renal insufficiency, acute or chronic inflammatory disease, pregnancy and perinatal women.

Design outcomes

Primary

MeasureTime frame
d-dimer;FDP;CTCs;SEN, SPE, ACC, AUC of ROC;—

Secondary

MeasureTime frame
thrombosis;image test;Pathological diagnosis;—

Countries

China

Contacts

Public ContactDiao Dongmei

The First Affiliated Hospital of Xi'an Jiaotong University

diaomei310@163.com+86 15902913963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026